Gday Poolboy. You have listed 4 risks that PAR may face getting their iPPS to enjoy lucrative sales in the future.
I would like to add a fifth. Edski1’s post early yesterday on another thread should ring a few alarm bells IMO.
Gid Bio’s research with stem cells for OA looks very promising at face value.
”88% of subjects responded greater than placebo at one year and reported a median 87% improvement in pain, stiffness and function.” And no AE.
Not too shabby I suggest. They are at roughly the same stage as PAR trying to gain FDA approval. i.e. about to begin phase III trials.
I don’t think we should dismiss this potential threat, or others as being too expensive.
They may be very competitive with price and efficacy.
In this race (or should I say crawl) to put an effective OA treatment on the market, the above example or alternative innovations could come through the pack and steal PAR’s crown or least reduce their reign drastically.
I am excited as anyone about the PAR future but we all know the old saying “when something sounds to good to be true, it usually is.”
Cheers MM
PAR Price at posting:
$1.69 Sentiment: Hold Disclosure: Held
(20min delay)